Page 7 - Ableson Tyrosine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Inhibikase Therapeutics (IKT) Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial

Inhibikase Therapeutics (IKT) Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAlex loboStroy freemanMiltonh wernerMilton wernerInhibikase therapeutics incExchange commissionAmerican academy of neurologyCompany contactParkinson progression marker initiativeSternir incWall streetProgression marker initiativeLancet neurologyAmerican academyInhibikase director

Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson s Disease

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase.

United statesMiltonh wernerStroy freemanAlex loboMilton wernerInhibikase or companyInhibikase therapeutics incExchange commissionAmerican academy of neurologyParkinson progression marker initiativeCompany contactSternir incInhibikase therapeuticsAbelson tyrosine kinasesProgression marker initiativeLancet neurology

Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase

Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAlex loboMilton wernerJoseph frattaroliMiltonh wernerLas vegasInhibikase therapeutics incHorseshoe hotel casinoExchange commissionSternir incCompany contactPrnewswire inhibikase therapeutics incInhibikase or companyCompany presentationsAbelson tyrosine kinasesChief executive officer

Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA, March 31, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of. | March 31, 2023

United statesMiltonh wernerAlex loboSternir incInhibikase or companyInhibikase therapeutics incExchange commissionPrnewswire inhibikase therapeutics incOffice of inhibikaseDrug administrationCompany contactAbelson tyrosine kinasesMultiple system atrophyChief executive officeStable phase chronic myelogenousUpcoming milestones

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMiltonh wernerAlex loboInhibikase therapeutics incInhibikase or companySternir incCompany contactInhibikase therapeuticsAbelson tyrosine kinasesAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophy